Join
Live feed
·
PRReleasevia Quantisnow
MyMD Pharmaceuticals Inc. logo

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

ByQuantisnow·Wall Street's wire, on your screen.
MYMD· MyMD Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MYMD (MyMD Pharmaceuticals Inc.) and more on Quantisnow.